The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy

Cancer Journal

Volumn 10, Issue 3, 2004, Pages 181-189

  Merrick, Gregory S ^a,b,c   Butler, Wayne M ^a,c   Wallner, Kent E ^a,d   Allen, Zachariah A ^a,b   Lief, Jonathan H ^a,b,c   Hinerman Mulroy, Ashley ^a,b   Galbreath, Robert W ^a,b,c  

^a Wheeling Hospital ^*

^b WHEELING HOSPITAL   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brachytherapy; Prostate; TURP; Urinary morbidity; Urinary retention

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SYMPTOMATOLOGY; URINE CATHETER; ADJUVANT THERAPY; AGED; CATHETERIZATION; DRUG EFFECT; METHODOLOGY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RADIOMETRY; URINARY TRACT;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RADIOMETRY; URINARY CATHETERIZATION; URINARY TRACT;

EID: 4644221955     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200405000-00008     Document Type: Article

References (27)

1. Merrick GS, Walhier KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003;169:1643-1652.
2. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. Urology 2003;62:786-792.
3. Merrick GS, Butler WM, Lief JH et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-128.
4. Merrick GS, Butler WM, Wallner KE et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:454-461.
5. Crook J, McLean M, Cation C et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
6. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-1382.
7. Crook J, Toi A, McLean M et al. The utility of transition zone index in predicting acute urinary morbidity after 1251 prostate brachytherapy. Brachytherapy 2002;1:131-137.
8. Tomlinson SK, Lee WR, McCullough DL et al. Neoadjuvant androgen deprivation increases the risk of acute urinary retention following low dose rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54[suppl]:273.
9. Locke J, Ellis W, Wallner K et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:712-719.
10. Merrick GS, Wallner KE, Butler WM. Patient selection for prostate brachytherapy: more myth than fact. Oncology 2004;18:445-452; discussion 452, 455-457.
11. 3: dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46:1199-1204.
12. Sherertz T, Wallner K, Wang H et al. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 2001;51:1241-1245.
13. Ash D, Flynn A, Battennann J et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-321.
14. Pedley ID. Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate. Surg Oncol 2002;11:25-34.
15. Merrick GS, Butler WM, Wallner KE et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Am J Clin Oncol 2004, in press.
16. Merrick GS, Butler WM, Lief JH et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy with or without supplemental external beam improve biochemical outcome for intermediate or high risk prostate cancer? B J U Int 2003;91:23-29.
17. Merrick GS, Butler WM, Tollenaar BG et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002;52:461-468.
18. Kang SK, Chou RH, Dodge RK et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys 2001;50:937-945.
19. Merrick GS, Butler WM, Farthing WH et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int 1998;14:112-121.
20. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design and evaluation. Tech Urol 2000;6:78-84.
21. Merrick GS, Butler WM, Dorsey AT et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 2001;7:233-240.
22. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: recommendations from the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-234.
23. Butler WM, Merrick GS, Dorsey AT et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:1575-1582.
24. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-1774.
25. Lee WR, McQuellon RP, Harris-Henderson K et al. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:77-81.
26. Keole S, Ben-Josef E, Cher M et al. Factors predicting acute urinary retention in patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54[suppl]:258-259.
27. Merrick GS, Butler WM, Wallner KE et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002;60:650-655.